文献速递甲状腺与颈部外科

甲状腺全切联合中央区淋巴结清扫与永久性甲状旁腺功能减退风险:人群研究

Central lymph node dissection and permanent hypoparathyroidism after total thyroidectomy for papillary thyroid cancer: population-based study.
PubMed 文献 · Br J Surg · 2021-01-01

基于瑞典甲状腺、甲状旁腺与肾上腺手术质量登记库,纳入2004年7月至2014年6月期间接受甲状腺全切或近全切(TT)的pT1-3期甲状腺乳头状癌患者722例,评估中央区淋巴结清扫(CLND)与永久性甲状旁腺功能减退的关系。

核心结论

  • CLND是甲状腺全切术后永久性甲状旁腺功能减退的独立危险因素。
  • 在TT+CLND患者中,淋巴结阴性者发生永久性甲状旁腺功能减退的风险更高。

研究设计与样本

  • 基于瑞典甲状腺、甲状旁腺与肾上腺手术质量登记库的人群研究,纳入2004年7月1日至2014年6月30日期间接受TT的pT1-3期甲状腺乳头状癌患者722例,并通过瑞典处方药登记库交叉核对用药情况。

关键数值与推荐

  • 永久性甲状旁腺功能减退定义为术后使用活性维生素D或口服钙剂超过6个月。
  • 研究比较TT+CLND组与单纯TT组永久性甲状旁腺功能减退发生率。

临床怎么用

  • 对pT1-3期甲状腺乳头状癌患者行TT时,应权衡CLND的获益与永久性甲状旁腺功能减退风险。
  • 对计划行CLND的患者,尤其淋巴结阴性者,应加强甲状旁腺功能保护与术后监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary thyroid cancer is treated with total/near-total thyroidectomy (TT) with or without central lymph node dissection (CLND), depending on risk factors and tumour size. Balancing the risk of disease recurrence and surgical morbidity remains a challenge. A population-based nationwide study was undertaken to evaluate the risk of permanent hypoparathyroidism associated with CLND. METHOD: Data on patients with stage pT1-3 papillary thyroid cancer, who underwent TT with or without CLND between 1 July 2004 and 30 June 2014 were retrieved from the Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery. Drug use was ascertained by cross-linking with the Swedish Prescribed Drug Register. Permanent hypoparathyroidism was defined as treatment with active D vitamin or oral calcium drugs for more than 6 months after surgery. Data were analysed separately for all patients and those who underwent TT + CLND. Univariable and multivariable logistic regression analyses were done, yielding odds ratios (ORs) with 95 per cent confidence intervals. RESULTS: A total of 722 patients were included in the study. Permanent hypoparathyroidism was more common in the TT + CLND group than the TT group: 30 of 265 patients (6·6 per cent) versus six of 457 (2·3 per cent) (P = 0·011). In multivariable logistic regression analysis, CLND was a risk factor for permanent hypoparathyroidism (OR 3·74, 95 per cent c.i. 1·46 to 9·59, based on use of combined therapy 6 months after surgery). In patients who had TT + CLND, node negativity was associated with a risk of permanent hypoparathyroidism (OR 3·08, 1·31 to 7·25). CONCLUSION: CLND is an independent risk factor for permanent hypoparathyroidism. Node negativity is associated with a higher risk of permanent hypoparathyroidism.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Salem FA, Bergenfelz A, Nordenström E, et al. Central lymph node dissection and permanent hypoparathyroidism after total thyroidectomy for papillary thyroid cancer: population-based study. Br J Surg. 2021. PMID: 34157088. doi:10.1002/bjs.12028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。